A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma & Leukemia
Hagop M KantarjianHervé Dombret

Abstract

Long-term disease-free survival in adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory, and the treatment options are limited for those patients with relapse or a failure to respond after initial therapy. We conducted a dose-escalation/expansion phase II, multicenter, single-arm study to determine the optimal dose of coltuximab ravtansine (SAR3419), an anti-CD19 antibody-drug conjugate, in this setting. The dose-escalation part of the study determined the selected dose of coltuximab ravtansine for the evaluation of efficacy and safety in the dose-expansion phase. Patients received coltuximab ravtansine induction therapy (≤ 8 weekly doses). The responding patients were eligible for maintenance therapy (biweekly administration for ≤ 24 weeks). Three dose levels of coltuximab ravtansine were examined: 55, 70, and 90 mg/m(2). The primary endpoint was the objective response rate (ORR). The secondary endpoints included the duration of response (DOR) and safety. A total of 36 patients were treated: 19 during dose escalation and 17 during dose expansion. One dose-limiting toxicity was observed at 90 mg/m(2) (grade 3 peripheral motor neuropathy); therefore, 70 mg/m(2) was selected for the dose-expansion phase. ...Continue Reading

References

May 24, 2005·Statistics in Medicine·Sally HunsbergerEdward L Korn
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
Jan 27, 2010·Cancer·Stefan FaderlHagop M Kantarjian
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Veronique BlancJohn M Lambert
Feb 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hernan CarolRichard B Lock
Sep 12, 2013·Cancer Management and Research·Ali RaufiAyad Al-Katib
Oct 18, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vincent RibragBertrand Coiffier
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Max S ToppRalf C Bargou

❮ Previous
Next ❯

Citations

Mar 5, 2016·Current Hematologic Malignancy Reports·Victor D FedorovAmir T Fathi
Aug 16, 2016·Leukemia Research·Nosha Farhadfar, Mark R Litzow
Sep 28, 2016·Expert Opinion on Drug Discovery·Francisco BautistaLucas Moreno
Sep 30, 2016·The International Journal of Neuroscience·Jie LinJunhui Xia
Nov 9, 2016·Expert Opinion on Emerging Drugs·Françoise Huguet, Suzanne Tavitian
Mar 30, 2017·Current Hematologic Malignancy Reports·Louise M ManMichael Keng
Jul 1, 2017·Blood Cancer Journal·T Terwilliger, M Abdul-Hay
Jul 1, 2017·Expert Review of Hematology·Gautam Kishore ValechaTerenig Terjanian
Jun 28, 2017·Pharmacotherapy·Clement Chung, Hilary Ma
Mar 21, 2018·Targeted Oncology·Cédric RossiRené-Olivier Casasnovas
Aug 6, 2018·Current Hematologic Malignancy Reports·Kathleen W Phelan, Anjali S Advani
Sep 22, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanSabina Chiaretti
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Anna Wolska-Washer, Tadeusz Robak
Sep 11, 2019·Journal of Hematology & Oncology·Bo Yu, Delong Liu
Aug 29, 2020·Expert Opinion on Biological Therapy·Roland B Walter
Jun 18, 2019·Therapeutic Advances in Hematology·Veronica A GuerraNicholas J Short
Aug 20, 2017·Journal of Hematology & Oncology·Guoqing WeiYanmin Zhao
Jan 16, 2021·Science·Katherine J SusaStephen C Blacklow
Apr 4, 2021·Cancers·Agata PastorczakMalgorzata Firczuk
May 18, 2021·Expert Opinion on Investigational Drugs·Andreas Viardot, Elisa Sala
Aug 28, 2021·Journal of Clinical Medicine·Jamie L Stokke, Deepa Bhojwani
May 18, 2020·European Journal of Cell Biology·Vladimír ČermákJan Brábek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.